Erythromycin/Isotretinoin

红霉素/异维甲酸

Report date: 2026/03/04 20:01:44

Base Information

Drug NameErythromycin/Isotretinoin
Drug Alias NameIsotretinoin/Erythromycin异维甲酸/红霉素异维A酸红霉素凝胶Isotrexin
ClassificationSmall molecules > Heterocyclic drugsSmall molecules > Heterocyclic drugs > Antibiotics > Macrolides antibiotics
Mechanisms of Action50S ribosomal subunit inhibitorsRetinoic acid receptors agonists
Targets50S ribosomal subunitRetinoic acid receptors
Therapy Area/IndicationsSkin UlcerAcne Vulgaris
Global Approved IndicationsSkin UlcerAcne Vulgaris
Approved Indications in ChinaSkin UlcerAcne Vulgaris
Original Approved Country/TerritoryEU
Original Approved DateN/A
Country/TerritoryEUMainland China
CombinationsYes ErythromycinIsotretinoin
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesGlaxosmithkline Uk Ltd
China Registration ClassN/A

Develop Information

Active CompaniesGlaxosmithkline Uk LtdSinopharm Wuhan Zhonglian Siyao Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsSkin UlcerAcne Vulgaris
Inactive IndicationsN/A

Other Information

ATC CodeD10AF52
Related LinksN/A